← FDA DRUG APPROVALS

FDA ANDA · ANDA211259

CLOBAZAM

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA211259
TYPE
ANDA
ORIGINAL APPROVAL
2018-10-22
LATEST ACTION
2023-05-01
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Discontinued

Products

CLOBAZAMDiscontinued
CLOBAZAM 2.5MG/ML · SUSPENSION · ORAL

Approval history

2023-05-01Labeling · Supplement 4 · standardAP
2022-02-11Labeling · Supplement 2 · standardAP
2019-07-19Manufacturing (CMC) · Supplement 1AP
2018-10-22UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →